Aquestive Therapeutics (AQST) Price to Sales (2018 - 2026)

Aquestive Therapeutics has reported Price to Sales for 9 years, with the latest figure at 37.78 in Q2 2026.

• On a quarterly basis, Price to Sales rose 14.93% year-over-year to 37.78 in Q2 2026; TTM through Jun 2026 was 9.65, a 29.55% increase from a year earlier, with the FY2025 full-year figure at 17.7, up 213.05% from the prior year.
• Price to Sales was 37.78 for Q2 2026 at Aquestive Therapeutics, up from 35.7 in the prior quarter.
• The five-year high for Price to Sales was 60.58 in Q4 2025, with the low at 2.57 in Q2 2022.
• Average Price to Sales over 5 years is 22.51, with a median of 18.9 recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Price to Sales plunged 74.21% in 2022, then surged 354.4% in 2024.
• Over 5 years, Price to Sales stood at 4.63 in 2022, then jumped by 126.4% to 10.48 in 2023, then surged by 161.6% to 27.42 in 2024, then jumped by 120.89% to 60.58 in 2025, then tumbled by 37.63% to 37.78 in 2026.
• The last three Price to Sales figures came in at 37.78 (Q2 2026), 35.7 (Q1 2026), and 60.58 (Q4 2025), per Business Quant data.